Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination With FOLFIRI for Patients With Previously Treated Metastatic Colorectal Cancer

NCT02482441 is registered in ClinicalTrials.gov with OncoMed Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02482441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02482441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination With FOLFIRI for Patients With Previously Treated Metastatic Colorectal Cancer
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 16, 2015
Completion date
March 28, 2018
Enrollment
50 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced relapsed tumors, refractory solid tumors